Despite only triggering low levels of tumor cell killing in vitro, Tras IgE treatment led to a significant reduction in JIMT-1 (HER2 2+) tumor volume (TGI=36.6%), as compared with PBS controls (figure 6D). Here, ERBB2 is linked to neoplasm.